España
India
Italia
대한민êµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Recent
Markets
Turing Pharmaceuticals
'Pharma Bro' Martin Shkreli Gets 7 Years In Prison For Securities Fraud
The Saga Of 'Pharma Bro' Martin Shkreli As He Heads To Trial
Turing Board Could Appoint Founder Martin Shkreli As Either CEO Or Chairman
The Saga Of 'Pharma Bro' Martin Shkreli As He Heads To Trial
Turing Board Could Appoint Founder Martin Shkreli As Either CEO Or Chairman
Turing Rejects $100 Million Offer For Daraprim
4 Crazy Wall Street Stories That Hollywood Should Pounce On
Turing Rejects $100 Million Offer For Daraprim
|
4 Crazy Wall Street Stories That Hollywood Should Pounce On
|
Martin Shkreli: Mallinckrodt Will Be Punished
|
Imprimis Signs Agreement With One Of Nation's Largest Pharmacy Benefit Managers; CEO Talks Disruption
|
Read More...
Turing Pharmaceuticals Recent News
Martin Shkreli Puts Up $45 Million E*Trade Account To Cover $5 Million Bailout
|
3 CEOs Who Made Headlines In 2015
|
KaloBios Plummets 50% After Martin Shkreli Is Arrested For Fraud
|
Express Scripts Prefers This $1 Alternative To Daraprim
|
Martin Shkreli ('The Most Hated Man On The Internet') Holds Reddit AMA And Gets 'Schooled' By A Doctor
|
Barron's Recap: Caring For Elderly Parents
|